UA61979C2 - Phenoxy alkylamine derivatives, a pharmaceutical composition and a method for treatment of mammals' diseases being accompanied by arrythmia - Google Patents

Phenoxy alkylamine derivatives, a pharmaceutical composition and a method for treatment of mammals' diseases being accompanied by arrythmia Download PDF

Info

Publication number: UA61979C2
Authority: UA; Ukraine
Prior art keywords: methyl; dimethylphenoxy; group; compounds; methylethyl
Prior art date: 1997-12-11

Application number

UA2000063362A

Other languages

English (en)

Ukrainian (uk)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-11

Filing date

1998-10-12

Publication date

2003-12-15

1998-10-12 Application filed filed Critical

2003-12-15 Publication of UA61979C2 publication Critical patent/UA61979C2/uk

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
206010003119 arrhythmia Diseases 0.000 title claims description 21
238000000034 method Methods 0.000 title claims description 20
241000124008 Mammalia Species 0.000 title claims description 4
201000010099 disease Diseases 0.000 title claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 3
-1 Phenoxy alkylamine Chemical class 0.000 title description 78
150000001875 compounds Chemical class 0.000 claims abstract description 138
150000003839 salts Chemical class 0.000 claims abstract description 32
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 28
239000001257 hydrogen Substances 0.000 claims abstract description 28
239000000203 mixture Substances 0.000 claims abstract description 26
230000003288 anthiarrhythmic effect Effects 0.000 claims abstract description 20
239000002253 acid Substances 0.000 claims abstract description 14
150000002431 hydrogen Chemical class 0.000 claims abstract description 13
229910052736 halogen Inorganic materials 0.000 claims abstract description 11
150000002367 halogens Chemical class 0.000 claims abstract description 10
125000003277 amino group Chemical group 0.000 claims abstract description 7
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 7
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims abstract description 4
150000004677 hydrates Chemical class 0.000 claims abstract description 3
239000002207 metabolite Substances 0.000 claims abstract description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
125000000217 alkyl group Chemical group 0.000 claims description 20
HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims description 20
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 19
238000002360 preparation method Methods 0.000 claims description 18
239000002904 solvent Substances 0.000 claims description 17
230000006793 arrhythmia Effects 0.000 claims description 16
239000003416 antiarrhythmic agent Substances 0.000 claims description 15
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 15
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 14
239000003814 drug Substances 0.000 claims description 5
229940079593 drug Drugs 0.000 claims description 4
239000000969 carrier Substances 0.000 claims description 3
150000007513 acids Chemical class 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 2
239000000654 additive Substances 0.000 claims 1
150000003254 radicals Chemical group 0.000 claims 1
239000002562 thickening agent Substances 0.000 claims 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 1
125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 1
125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
239000000243 solution Substances 0.000 description 28
239000000126 substance Substances 0.000 description 26
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
238000006243 chemical reaction Methods 0.000 description 17
230000000694 effects Effects 0.000 description 17
238000002844 melting Methods 0.000 description 17
230000008018 melting Effects 0.000 description 17
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
239000013078 crystal Substances 0.000 description 15
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 13
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 13
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
210000004351 coronary vessel Anatomy 0.000 description 12
239000003921 oil Substances 0.000 description 12
230000002829 reductive effect Effects 0.000 description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
239000011541 reaction mixture Substances 0.000 description 10
229910052709 silver Inorganic materials 0.000 description 9
241000282472 Canis lupus familiaris Species 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
230000009471 action Effects 0.000 description 7
239000012074 organic phase Substances 0.000 description 7
230000001536 pro-arrhythmogenic effect Effects 0.000 description 7
229960002370 sotalol Drugs 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
230000036982 action potential Effects 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
238000004296 chiral HPLC Methods 0.000 description 6
238000001704 evaporation Methods 0.000 description 6
230000008020 evaporation Effects 0.000 description 6
230000000297 inotrophic effect Effects 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
238000003756 stirring Methods 0.000 description 6
238000005303 weighing Methods 0.000 description 6
238000004440 column chromatography Methods 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
NXXYKOUNUYWIHA-UHFFFAOYSA-N 2,6-Dimethylphenol Chemical compound CC1=CC=CC(C)=C1O NXXYKOUNUYWIHA-UHFFFAOYSA-N 0.000 description 4
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000008602 contraction Effects 0.000 description 4
230000037024 effective refractory period Effects 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
238000005259 measurement Methods 0.000 description 4
210000003540 papillary muscle Anatomy 0.000 description 4
210000003742 purkinje fiber Anatomy 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
239000000725 suspension Substances 0.000 description 4
230000002861 ventricular Effects 0.000 description 4
FSTWMOUDEJBNAO-UHFFFAOYSA-N 2-[4-(methanesulfonamido)phenyl]acetic acid Chemical compound CS(=O)(=O)NC1=CC=C(CC(O)=O)C=C1 FSTWMOUDEJBNAO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
206010058156 Reperfusion arrhythmia Diseases 0.000 description 3
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
239000008346 aqueous phase Substances 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
238000009835 boiling Methods 0.000 description 3
230000000747 cardiac effect Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
210000000038 chest Anatomy 0.000 description 3
238000007865 diluting Methods 0.000 description 3
239000003480 eluent Substances 0.000 description 3
230000002349 favourable effect Effects 0.000 description 3
238000001914 filtration Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
208000028867 ischemia Diseases 0.000 description 3
239000012280 lithium aluminium hydride Substances 0.000 description 3
235000015097 nutrients Nutrition 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
238000011084 recovery Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000002336 repolarization Effects 0.000 description 3
VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
NTURQZFFJDCTMZ-UHFFFAOYSA-N 1-(2-bromoethyl)-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(CCBr)C=C1 NTURQZFFJDCTMZ-UHFFFAOYSA-N 0.000 description 2
NKTOLZVEWDHZMU-UHFFFAOYSA-N 2,5-xylenol Chemical compound CC1=CC=C(C)C(O)=C1 NKTOLZVEWDHZMU-UHFFFAOYSA-N 0.000 description 2
CRBJBYGJVIBWIY-UHFFFAOYSA-N 2-isopropylphenol Chemical compound CC(C)C1=CC=CC=C1O CRBJBYGJVIBWIY-UHFFFAOYSA-N 0.000 description 2
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
206010011086 Coronary artery occlusion Diseases 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
239000012359 Methanesulfonyl chloride Substances 0.000 description 2
LGDSHSYDSCRFAB-UHFFFAOYSA-N Methyl isothiocyanate Chemical compound CN=C=S LGDSHSYDSCRFAB-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
125000000278 alkyl amino alkyl group Chemical group 0.000 description 2
125000003806 alkyl carbonyl amino group Chemical group 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000007906 compression Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000004821 distillation Methods 0.000 description 2
229960002994 dofetilide Drugs 0.000 description 2
IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000007429 general method Methods 0.000 description 2
230000009931 harmful effect Effects 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
VLPIATFUUWWMKC-UHFFFAOYSA-N mexiletine Chemical compound CC(N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-UHFFFAOYSA-N 0.000 description 2
229960003404 mexiletine Drugs 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000010410 reperfusion Effects 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
BUJAGSGYPOAWEI-SECBINFHSA-N (2r)-2-amino-n-(2,6-dimethylphenyl)propanamide Chemical compound C[C@@H](N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-SECBINFHSA-N 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
XCBOFCZRZZXQKG-UHFFFAOYSA-N 1-(2,3,5-trimethylphenoxy)propan-2-amine Chemical compound CC(N)COC1=CC(C)=CC(C)=C1C XCBOFCZRZZXQKG-UHFFFAOYSA-N 0.000 description 1
XRUNSJZVEXVAFH-UHFFFAOYSA-N 1-(2,5-dimethylphenoxy)propan-2-ol Chemical compound CC(O)COC1=CC(C)=CC=C1C XRUNSJZVEXVAFH-UHFFFAOYSA-N 0.000 description 1
GXKJODUDPCAIAG-UHFFFAOYSA-N 1-(2,6-dimethylphenoxy)-n-methylpropan-2-amine Chemical compound CNC(C)COC1=C(C)C=CC=C1C GXKJODUDPCAIAG-UHFFFAOYSA-N 0.000 description 1
SFFPPLGNVPIMGM-UHFFFAOYSA-N 1-(2-propan-2-ylphenoxy)propan-2-ol Chemical compound CC(O)COC1=CC=CC=C1C(C)C SFFPPLGNVPIMGM-UHFFFAOYSA-N 0.000 description 1
125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
QFFKNTCASXEPOQ-UHFFFAOYSA-N 2-(2,3-dimethylphenoxy)ethanamine Chemical compound CC1=CC=CC(OCCN)=C1C QFFKNTCASXEPOQ-UHFFFAOYSA-N 0.000 description 1
CSEWAUGPAQPMDC-UHFFFAOYSA-N 2-(4-aminophenyl)acetic acid Chemical compound NC1=CC=C(CC(O)=O)C=C1 CSEWAUGPAQPMDC-UHFFFAOYSA-N 0.000 description 1
CBCWYSYBRINEON-UHFFFAOYSA-N 2-(methanesulfonamido)-2-phenylacetic acid Chemical compound CS(=O)(=O)NC(C(O)=O)C1=CC=CC=C1 CBCWYSYBRINEON-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
206010003658 Atrial Fibrillation Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
101000939500 Homo sapiens UBX domain-containing protein 11 Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
GOOHAUXETOMSMM-VKHMYHEASA-N S-propylene oxide Chemical compound C[C@H]1CO1 GOOHAUXETOMSMM-VKHMYHEASA-N 0.000 description 1
108010052164 Sodium Channels Proteins 0.000 description 1
102000018674 Sodium Channels Human genes 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
206010042434 Sudden death Diseases 0.000 description 1
208000002847 Surgical Wound Diseases 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
102100029645 UBX domain-containing protein 11 Human genes 0.000 description 1
RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
125000004442 acylamino group Chemical group 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
125000005422 alkyl sulfonamido group Chemical group 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000767 anti-ulcer Effects 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940127088 antihypertensive drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
229910052785 arsenic Inorganic materials 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000003177 cardiotonic effect Effects 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
235000013351 cheese Nutrition 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
229950009941 chloralose Drugs 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
229940082627 class iii antiarrhythmics Drugs 0.000 description 1
239000013058 crude material Substances 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
238000011161 development Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
LBTPIFQNEKOAIM-UHFFFAOYSA-N n-phenylmethanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1 LBTPIFQNEKOAIM-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000009090 positive inotropic effect Effects 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
239000003087 receptor blocking agent Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000013577 regulation of ventricular cardiomyocyte membrane repolarization Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
239000003195 sodium channel blocking agent Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
OTNVGWMVOULBFZ-UHFFFAOYSA-N sodium;hydrochloride Chemical compound [Na].Cl OTNVGWMVOULBFZ-UHFFFAOYSA-N 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
239000000829 suppository Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
229960002872 tocainide Drugs 0.000 description 1
238000009901 transfer hydrogenation reaction Methods 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
208000003663 ventricular fibrillation Diseases 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C335/20—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

UA2000063362A 1997-12-11 1998-10-12 Phenoxy alkylamine derivatives, a pharmaceutical composition and a method for treatment of mammals' diseases being accompanied by arrythmia UA61979C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU9702411A HUP9702411A2 (hu)	1997-12-11	1997-12-11	Fenoxi-alkil-amin-származékok és a vegyületeket tartalmazó antiaritmiás hatású gyógyszerkészítmények
PCT/HU1998/000101 WO1999029655A1 (en)	1997-12-11	1998-12-10	Novel antiarrhythmic compounds

Publications (1)

Publication Number	Publication Date
UA61979C2 true UA61979C2 (en)	2003-12-15

Family

ID=89995855

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2000063362A UA61979C2 (en)	1997-12-11	1998-10-12	Phenoxy alkylamine derivatives, a pharmaceutical composition and a method for treatment of mammals' diseases being accompanied by arrythmia

Country Status (22)

Country	Link
US (1)	US6265445B1 (de)
EP (1)	EP1037871B1 (de)
JP (1)	JP2001525388A (de)
KR (1)	KR100576905B1 (de)
CN (1)	CN1140498C (de)
AT (1)	ATE220058T1 (de)
AU (1)	AU738672B2 (de)
BR (1)	BR9814270A (de)
CA (1)	CA2313191A1 (de)
DE (1)	DE69806411T2 (de)
DK (1)	DK1037871T3 (de)
ES (1)	ES2179547T3 (de)
HU (1)	HUP9702411A2 (de)
IL (1)	IL136659A (de)
NO (1)	NO20002946L (de)
NZ (1)	NZ504982A (de)
PL (1)	PL190788B1 (de)
PT (1)	PT1037871E (de)
RU (1)	RU2193024C2 (de)
SK (1)	SK284284B6 (de)
UA (1)	UA61979C2 (de)
WO (1)	WO1999029655A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19956786A1 (de) *	1999-11-25	2001-05-31	Basf Ag	Verfahren zur Herstellung optisch aktiver Amine
US20030119406A1 (en)	2001-12-20	2003-06-26	Abuto Francis Paul	Targeted on-line stabilized absorbent structures
WO2003091205A1 (fr) *	2002-04-26	2003-11-06	Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences	Sulfamidophenylalkylamines, production et utilisation de ces dernieres
CN102603543B (zh) *	2012-04-09	2014-07-02	佛山普正医药科技有限公司	一种盐酸美西律的生产方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DD146749A3 (de) *	1977-12-01	1981-03-04	Dieter Lehmann	Verfahren zur herstellung von phenoxyalkanolamin-derivaten
EG18188A (en) *	1986-05-01	1992-09-30	Pfizer Ltd	Process for preparation anti-arhythmia agents
NO179246C (no) *	1991-11-20	1996-09-04	Sankyo Co	Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
JPH06107614A (ja) *	1992-09-26	1994-04-19	Arakusu:Kk	アリールスルホン酸アミド類またはアリールカルボン酸アミド類及びそれらの薬剤として許容される酸付加塩及びその製造法並びにそれを有効成分とする抗消化性潰瘍剤

1997
- 1997-12-11 HU HU9702411A patent/HUP9702411A2/hu unknown
1998
- 1998-10-12 UA UA2000063362A patent/UA61979C2/uk unknown
- 1998-12-10 PT PT98961331T patent/PT1037871E/pt unknown
- 1998-12-10 KR KR1020007006348A patent/KR100576905B1/ko not_active Expired - Fee Related
- 1998-12-10 IL IL13665998A patent/IL136659A/en not_active IP Right Cessation
- 1998-12-10 AT AT98961331T patent/ATE220058T1/de not_active IP Right Cessation
- 1998-12-10 US US09/555,602 patent/US6265445B1/en not_active Expired - Fee Related
- 1998-12-10 JP JP2000524252A patent/JP2001525388A/ja active Pending
- 1998-12-10 DE DE69806411T patent/DE69806411T2/de not_active Expired - Lifetime
- 1998-12-10 AU AU16789/99A patent/AU738672B2/en not_active Ceased
- 1998-12-10 PL PL341107A patent/PL190788B1/pl not_active IP Right Cessation
- 1998-12-10 SK SK879-2000A patent/SK284284B6/sk not_active IP Right Cessation
- 1998-12-10 WO PCT/HU1998/000101 patent/WO1999029655A1/en not_active Ceased
- 1998-12-10 ES ES98961331T patent/ES2179547T3/es not_active Expired - Lifetime
- 1998-12-10 EP EP98961331A patent/EP1037871B1/de not_active Expired - Lifetime
- 1998-12-10 NZ NZ504982A patent/NZ504982A/en unknown
- 1998-12-10 CN CNB988135779A patent/CN1140498C/zh not_active Expired - Fee Related
- 1998-12-10 DK DK98961331T patent/DK1037871T3/da active
- 1998-12-10 BR BR9814270-4A patent/BR9814270A/pt not_active Application Discontinuation
- 1998-12-10 RU RU2000118325/04A patent/RU2193024C2/ru not_active IP Right Cessation
- 1998-12-10 CA CA002313191A patent/CA2313191A1/en not_active Abandoned
2000
- 2000-06-08 NO NO20002946A patent/NO20002946L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PT1037871E (pt)	2002-11-29
RU2193024C2 (ru)	2002-11-20
JP2001525388A (ja)	2001-12-11
NZ504982A (en)	2002-07-26
CN1284941A (zh)	2001-02-21
NO20002946L (no)	2000-08-07
HK1033937A1 (en)	2001-10-05
KR20010032996A (ko)	2001-04-25
AU1678999A (en)	1999-06-28
NO20002946D0 (no)	2000-06-08
CA2313191A1 (en)	1999-06-17
EP1037871A1 (de)	2000-09-27
HUP9702411A2 (hu)	2000-03-28
DK1037871T3 (da)	2002-10-14
DE69806411D1 (de)	2002-08-08
SK284284B6 (sk)	2005-01-03
PL190788B1 (pl)	2006-01-31
ES2179547T3 (es)	2003-01-16
WO1999029655A1 (en)	1999-06-17
IL136659A (en)	2004-08-31
PL341107A1 (en)	2001-03-26
US6265445B1 (en)	2001-07-24
HU9702411D0 (en)	1998-03-02
BR9814270A (pt)	2001-10-16
SK8792000A3 (en)	2001-02-12
IL136659A0 (en)	2001-06-14
CN1140498C (zh)	2004-03-03
AU738672B2 (en)	2001-09-20
ATE220058T1 (de)	2002-07-15
DE69806411T2 (de)	2003-03-20
EP1037871B1 (de)	2002-07-03
KR100576905B1 (ko)	2006-05-03

Publication	Publication Date	Title
EP0178874B1 (de)	1989-04-05	Alkylsulfonamidophenylalkylamine
US6656971B2 (en)	2003-12-02	Trisubstituted carbocyclic cyclophilin binding compounds and their use
US5449689A (en)	1995-09-12	Naphthylethylureas and naphthylethylthioureas
PT91931B (pt)	1995-05-31	Processo de preparacao de derivados de acido fenilalcanoico e de composicoes farmaceuticas que os contem
EP1032556B1 (de)	2007-12-19	Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
DE69102503T2 (de)	1994-11-24	N-Phenyl-N'-alkylsulfonylharnstoffe, Verfahren zu ihrer Herstellung und diese enthaltende Antitumorzusammensetzungen.
EP1300142A1 (de)	2003-04-09	Hypoglycemische verbindungen
CA2338968C (en)	2010-04-27	Glucocorticoid-selective agents
US6812252B2 (en)	2004-11-02	Acylsulfonamide derivatives
JPS62267250A (ja)	1987-11-19	抗不整脈剤
RU2193024C2 (ru)	2002-11-20	Новые антиаритмические соединения
PT98684A (pt)	1992-07-31	Processo de preparacao de derivados da difenilureia e de composicoes farmaceuticas contendo os mesmos
US5677328A (en)	1997-10-14	Ethylamino carbazole melatonergic agents
MXPA00005768A (en)	2002-05-09	Novel antiarrhythmic compounds
MX2008011589A (es)	2008-09-22	2-amino-4-fenildihidroquinolinas sustituidas, metodo para su produccion, su uso como medicamento y medicamentos que las contienen.
BRPI0708818A2 (pt)	2011-06-14	1-amino-4-fenil-diidroisoquinolinas substituÍdas, mÉtodo para a produÇço das mesmas, uso das mesmas como um medicamento e medicamento contendo-as
CZ296071B6 (cs)	2006-01-11	Antiarytmické fenoxyalkylaminové deriváty
JPH0357892B2 (de)	1991-09-03
AU695337C (en)	1999-09-02	Therapeutic substituted guanidines
HK1033937B (en)	2004-12-24	Novel antiarrhythmic compounds
US3923886A (en)	1975-12-02	Sulfamides
AU7047394A (en)	1994-12-20	Therapeutic substituted guanidines
JPH10505829A (ja)	1998-06-09	抗不整脈活性を有する４−（４−メタンスルホンアミドフェニル）ブチルアミン誘導体